|
|
|
1-10 employees
View all
|
|
Pharmaceuticals
|
|
5 Laboratory Dr, Durham, North Carolina 27709, US
|
|
Bantam Pharmaceutical is a drug discovery company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial dynamics, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for Its lead candidate, BTM-3566, in B-cell malignancies.
About BTM-3566
BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique from any other therapeutic, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is currently underway and will be completed by Q1 2022.
|
Bantam Pharmaceutical Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Bantam Pharmaceutical email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Bantam Pharmaceutical customer service number in your country click here to find.
Michael Stocum is the CEO of Bantam Pharmaceutical. To contact Michael Stocum email at [email protected] or [email protected]. Or you may call +1.9198558399 or +1.9197831896
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.